In conclusion, the findings of this study demonstrate that although the PERK pathway is transiently activated after a focal/diffuse brain injury, oral treatment with the PERK inhibitor, GSK2606414, did not attenuate TBI-induced deficits. The gene discussed is EIF2AK3; the disease is brain injury.